TriSalus Life Sciences Business Summary

TriSalus Life Sciences, Inc. (TLSI) operates a high-growth business model centered on the commercialization of its proprietary Pressure-Enabled Drug Delivery (PEDD) technology, primarily generating revenue through the sale of the FDA-cleared TriNav Infusion System and the TriNav Flex. The company’s operations are bifurcated into a commercial-stage MedTech division, which leverages pressure-modulation devices to enhance drug delivery to solid tumors, and a clinical-stage Therapeutics division developing nelitolimod (SD-101), an investigational TLR9 agonist. With 2025 revenues of approximately $45.2 million and 2026 guidance projected at $60–$62 million, TriSalus is scaling rapidly within the interventional oncology market. Its primary competitors include RenovoRx, Merit Medical Systems, and Boston Scientific; TriSalus distinguishes itself by combining specialized delivery hardware with a proprietary immunotherapy candidate to address the high interstitial fluid pressure that typically limits treatment efficacy in liver and pancreatic cancers. The executive leadership is spearheaded by President and CEO Mary Szela, a prominent industry veteran with over 35 years of experience, including her tenure as President of Abbott Laboratories' $8 billion U.S. pharmaceutical business and CEO of Novelion Therapeutics. Financial strategy is directed by CFO David B. Patience, who joined in July 2025 with a background in capital markets from Accelerate Diagnostics, while commercial and clinical operations are managed by Dr. Richard B. Marshak and Jodi Devlin, both of whom hold extensive leadership pedigrees from Abbott. The company’s strategic direction is supported by a board led by Chairman Mats Wahlström, former CEO of Fresenius Medical Care North America, and recently appointed director Michael P. Stansky, a veteran healthcare investor from Tudor Investment Corporation. This leadership team is backed by institutional investors and a governance structure focused on transitioning the firm toward Adjusted EBITDA positivity by mid-2026.